The bonebridge as a transcutaneous bone conduction hearing system: preliminary surgical and audiological results in children and adolescents

The Bonebridge ^® (BB, Med-El) is a newly designed transcutaneous active bone conductive implant with functional outcome similar to percutaneous bone-anchored hearing systems (BAHS). It is currently approved only for patients ≥18 years. Since the BB allows the skin to remain intact and therefore should be able to overcome some of the issues related to percutaneous BAHS including skin reactions, wound infection and implant extrusion, it would be especially attractive for use in children. We present a preliminary series of the first three cases of BB implantation in children/adolescents (10–16 years). Two subjects were affected by conductive hearing loss (CHL) and one subject by single-sided deafness (SSD). The surgical procedure with transmastoid approach was completed in all cases without complications. Both subjects with CHL showed an increase in speech perception thresholds in quiet from preoperative unaided to 6 months postoperatively with BB of 37 dB, respectively, of 12 dB. The adolescent with SSD attained –3.1 dB unaided vs. –5.6 dB with the BB in the “speech and noise from the front” presentation and +0.5 unaided vs. –5.0 dB with the BB in the “speech from the unilateral deaf side/noise from the normal hearing side” presentation using the adaptive Oldenburg Sentence Test. The results show a straightforward surgical procedure and satisfactory functional gain after BB implantation also in children/adolescents. BB implantation in patients ≤18 years is currently an “off-label use” so that detailed information about alternative treatment options, operation risks and the lack of approval for use in children is essential.